Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CRNX on Nasdaq
Shares outstanding
94,179,674
Price per share
$46.55
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
107,702,230
Total reported value
$4,486,005,349
% of total 13F portfolios
0%
Share change
+3,144,668
Value change
+$149,678,962
Number of holders
224
Price from insider filings
$46.55
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +46% $466,033,211 +$144,432,819 13,957,269 +45% FMR LLC 31 Mar 2025
VANGUARD GROUP INC 10% +2% $310,914,324 +$7,419,559 9,311,600 +2.4% The Vanguard Group 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 8.9% +45% $349,109,925 +$107,235,547 8,381,991 +44% Wellington Management Group LLP 30 Sep 2025
Farallon Capital Partners, L.P. 6% $164,477,866 5,625,098 Dapice Joshua J. 29 Aug 2025

As of 30 Sep 2025, 224 institutional investors reported holding 107,702,230 shares of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX). This represents 114% of the company’s total 94,179,674 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) together control 94% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 14,187,498 +0.44% 0.03% $590,909,308
VANGUARD GROUP INC 9.7% 9,170,129 -0.93% 0.01% $381,935,873
WELLINGTON MANAGEMENT GROUP LLP 8.9% 8,381,991 +44% 0.06% $349,109,926
BlackRock, Inc. 8.1% 7,586,597 +2.3% 0.01% $315,981,777
Driehaus Capital Management LLC 6.9% 6,481,613 +1.3% 1.9% $269,959,181
FARALLON CAPITAL MANAGEMENT LLC 6.1% 5,770,098 +24% 1.4% $240,324,582
PRICE T ROWE ASSOCIATES INC /MD/ 5.6% 5,306,248 -5.1% 0.02% $221,006,000
EcoR1 Capital, LLC 4.6% 4,288,120 0% 8.6% $178,600,198
JANUS HENDERSON GROUP PLC 4.1% 3,858,791 +13% 0.07% $160,695,917
Paradigm Biocapital Advisors LP 2.7% 2,550,774 +8.8% 3.1% $106,239,737
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,278,830 +3% 0.01% $94,926,353
STATE STREET CORP 2.3% 2,207,707 -32% 0% $91,950,997
JENNISON ASSOCIATES LLC 2.2% 2,044,734 +2.9% 0.05% $85,163,170
Point72 Asset Management, L.P. 2.1% 2,003,333 +0.26% 0.18% $83,438,803
Siren, L.L.C. 1.8% 1,688,611 0% 2.8% $70,330,648
NOVO HOLDINGS A/S 1.7% 1,625,000 +4.8% 4.4% $67,681,250
Pictet Asset Management Holding SA 1.6% 1,465,262 +22% 0.06% $61,028,162
JPMORGAN CHASE & CO 1.3% 1,258,722 +279% 0% $52,425,771
AMERICAN CENTURY COMPANIES INC 1.2% 1,133,535 +34% 0.02% $47,211,782
ORBIMED ADVISORS LLC 1.2% 1,099,000 -4.4% 1.1% $45,773,350
First Light Asset Management, LLC 1% 941,516 +9% 3.7% $39,214,141
CITADEL ADVISORS LLC 0.94% 884,507 +35% 0.03% $36,839,717
Hood River Capital Management LLC 0.94% 883,004 -0.62% 0.43% $36,777,117
RTW INVESTMENTS, LP 0.93% 872,387 +87% 0.45% $36,334,919
GW&K Investment Management, LLC 0.9% 850,546 -12% 0.31% $35,425,000

Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 748,706 $34,852,275 +$11,263,055 $46.55 15
2025 Q3 107,702,230 $4,486,005,349 +$149,678,962 $41.65 224
2025 Q2 104,559,713 $3,007,383,972 +$75,026,414 $28.76 220
2025 Q1 101,790,412 $3,418,305,905 +$9,856,311 $33.54 225
2024 Q4 99,690,161 $5,097,004,672 +$758,098,969 $51.13 245
2024 Q3 84,525,573 $4,321,960,073 +$33,724,194 $51.10 233
2024 Q2 82,487,807 $3,694,594,767 +$92,152,096 $44.79 232
2024 Q1 80,384,076 $3,762,661,947 +$486,785,470 $46.81 201
2023 Q4 70,656,199 $2,513,959,167 +$68,274,571 $35.58 180
2023 Q3 68,535,017 $2,038,114,354 +$440,832,585 $29.74 171
2023 Q2 54,057,835 $974,084,774 -$11,795,159 $18.02 138
2023 Q1 55,062,782 $884,310,368 +$2,280,401 $16.06 127
2022 Q4 54,817,398 $1,003,122,430 -$14,306,281 $18.30 121
2022 Q3 51,456,378 $1,010,816,996 +$16,147,822 $19.64 118
2022 Q2 50,645,843 $944,532,132 +$94,595,270 $18.65 109
2022 Q1 45,482,453 $997,426,956 -$15,117,112 $21.95 114
2021 Q4 44,273,322 $1,256,550,441 +$251,517,738 $28.41 114
2021 Q3 33,632,624 $708,150,662 +$17,177,215 $21.05 91
2021 Q2 32,726,853 $616,933,642 +$42,446,903 $18.85 81
2021 Q1 30,730,499 $465,273,247 +$5,520,857 $15.28 78
2020 Q4 30,426,213 $429,299,885 -$4,592,533 $14.11 84
2020 Q3 30,337,604 $475,397,972 -$19,900,117 $15.67 70
2020 Q2 31,451,376 $546,085,663 +$188,712,886 $17.52 79
2020 Q1 20,679,487 $303,862,789 +$45,411,611 $14.70 55
2019 Q4 17,526,211 $439,727,847 -$5,476,519 $25.09 58
2019 Q3 15,234,699 $229,128,583 -$94,271,503 $15.04 60
2019 Q2 18,931,321 $473,283,223 +$31,131,935 $25.00 63
2019 Q1 17,737,322 $403,697,060 +$20,738,652 $22.76 62
2018 Q4 16,786,897 $503,433,000 +$19,006,654 $29.99 50
2018 Q3 16,164,902 $463,124,000 +$463,124,002 $28.65 49